BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessAbeona Therapeutics Receives FDA Orphan Drug Designation for EB-101 Gene Therapy Product for Patients with Epidermolysis BullosaBy Nasdaq OMXMay 25, 2017, 12:10 PM UTC
BusinessCURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.By Nasdaq OMXMay 24, 2017, 1:12 PM UTC
BusinessCURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.By Nasdaq OMXMay 24, 2017, 1:11 PM UTC
BusinessCURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.By Nasdaq OMXMay 24, 2017, 1:11 PM UTC
BusinessCURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.By Nasdaq OMXMay 24, 2017, 1:11 PM UTC
BusinessCURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.By Nasdaq OMXMay 24, 2017, 1:11 PM UTC
BusinessCURE Pharmaceutical Receives First Purchase Order Stemming from Product Development and License Agreement with Pharmaceutical Company, Meroven LTD.By Nasdaq OMXMay 24, 2017, 1:11 PM UTC
